Medical Industry Feature

Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma


Listen Later

Guest: Mateo Mejia Saldarriaga, M.D.

Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days.

© 2025 NewYork-Presbyterian

...more
View all episodesView all episodes
Download on the App Store

Medical Industry FeatureBy ReachMD

  • 4
  • 4
  • 4
  • 4
  • 4

4

1 ratings


More shows like Medical Industry Feature

View all
SexMed by ReachMD

SexMed

3 Listeners

Partners in Practice by ReachMD

Partners in Practice

3 Listeners

Second Opinion LIVE! by ReachMD

Second Opinion LIVE!

0 Listeners

Medical Breakthroughs from Penn Medicine by ReachMD

Medical Breakthroughs from Penn Medicine

6 Listeners

Advances in Women's Health by ReachMD

Advances in Women's Health

14 Listeners

GI Insights by ReachMD

GI Insights

18 Listeners

Conference Coverage by ReachMD

Conference Coverage

0 Listeners